PODCAST: A Bubble Tea IPO Freeze, and a Revenue-less Drug Maker
China's securities regulator puts the brakes on new bubble tea IPOs in Hong Kong. Is this China's latest step to assert its authority over the former British colony? And former drug making highflyer Ascletis has become revenue-less after its earlier drugs fizzled. Now the company is hoping to revive its fortunes with a new weight-loss drug from the same class as Ozempic.
PODCAST: WeRide’s Spin with Uber, and Starbucks’ New China CEO
Uber will offer WeRide robotaxi services starting in the UAE. Is this a big deal, or mostly symbolic? And Starbucks names a new China CEO to revive its flagging local operation. Will that be enough to tackle the challenge from low-price companies like Luckin and Cotti?
U.S.-China stock cooperation moves ahead with fines on two PwC China affiliates
The U.S. securities regulator’s accounting arm fined PwC’s Hong Kong and Shanghai units $7 million after hundreds of their workers cheated on online training tests Key Takeaways: The accounting arm…
PODCAST: Ant Group and Tencent slapped with fines, and Freshippo steps up for IPO
China’s central bank has slapped major fines on Ant Group and Tencent, including a nearly $1 billion fine on Ant, operator of Alipay. Is this the start of a new round of big fines on China’s big tech? Or does it mark the end of a recent storm of regulation that began after outspoken Alibaba founder Jack Ma criticized the government?
In ‘Summer of Regulation,’ Companies Should Look for Positives
By Doug Young When God gives you lemons, make lemonade. Ok, maybe that’s just slightly cliché. But the old saying could also offer some words of wisdom for companies and…
Lexin Slows Down Lending as Latest Regulatory Wave Rocks Fintechs
Company scales back 2021 loan facilitation goals amid latest talk that Beijing could sharply lower interest rate cap for personal loans Key Takeaways: • LexinFintech is voluntarily slowing down its…
Recent Articles
RELATED ARTICLES
-
Mixue pours up strong growth in China’s overheated bubble tea market
- IPO tea party set to resume with Guming’s regulatory nod from China?
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
- Weak sentiment may leave Auntea Jenny thirsty for better valuation
